NCT00181714View on ClinicalTrials.gov

Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta

PHASE4CompletedINTERVENTIONAL

Enrollment

203

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

ADHD

Interventions

DRUG

methylphenidate HCl (Concerta)

OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.

Trial Locations (1)

02138

Massachusetts General Hospital, Cambridge

All Listed Sponsors

collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00181714 - Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta | Biotech Hunter | Biotech Hunter